China launch of serotonin-agonist anti-anxiety drug Sediel®
Sumitomo Pharmaceuticals Co., Ltd. announces the February 2004 launch of the serotonin-agonist anti-anxiety drug Sediel (generic name: tandospirone citrate) in the People's Republic of China.
Since obtaining permission from the State Food and Drug Administration of the People's Republic of China, effective May 21, 2003, for the importation and sale of Sediel, Sumitomo Pharmaceuticals has been engaged in preparations for its marketing, which include the training and development of MRs (Medical Representatives). With the official registration of the price on December 26, 2003, the drug came on the market under the name Sediel, recognized as effective in the treatment of generalized anxiety disorders.
To commemorate the drug's release, the company invited medical specialists in the field of mental health from both Japan and China, including Professor Osamu Tajima of the Kyorin University School of Health Sciences, to give special lectures in Beijing and Shanghai on February 19 and 20, respectively.
Sediel is a new type of anti-anxiety drug, different from the benzodiazepines, that was developed independently by Sumitomo Pharmaceuticals. It has been available in Japan since December 1996, and is recognized for its effectiveness in treating psychosomatic and neurotic disorders. Sediel acts selectively only on the serotonin receptors in the brain that are important to the formation of anxiety and depression, and demonstrates both anti-anxiety and anti-depression effects.
As China modernizes, stress is reportedly taking hold in society in the same way it did in Japan. Thus Sediel, an anti-anxiety drug with little adverse impact on day-to-day living, can also make a useful contribution in China.
Sumitomo Pharmaceuticals has established Beijing and Shanghai offices as bases for its activities in China, promoting the products Mepem (Meropen in Japan), a carbapenem antibiotic, Almarl, a therapeutic agent for hypertension, and Cefpiran (Sepatren in Japan), a cephalosporin antibiotic, through its own medical representatives. In addition to expanding the sales of these products, the company will also actively bolster the market penetration of Sediel.